Chinese package insert for Kadcyla (trastuzumab emtansine) 100 mg and 160 mg for injection: indications, dosing, dose adjustment tables and warnings.
This is the Chinese package insert for Kadcyla (赫赛莱), trastuzumab emtansine for injection, a HER2-targeted antibody-drug conjugate supplied as a white to off-white sterile lyophilized powder for intravenous infusion in 100 mg and 160 mg vials. It states the drug name, active ingredient and excipients, molecular weight, description, indications in early and metastatic HER2-positive breast cancer, and the available strengths.
The document sets out the recommended dose of 3.6 mg/kg every three weeks, the 90-minute first infusion with observation for at least 90 minutes and the possible 30-minute later infusions, treatment duration for early and advanced breast cancer, dose-reduction levels and dose-adjustment tables for liver enzyme, bilirubin, platelet, left ventricular and pulmonary events, dosing in special populations, and instructions for reconstitution, handling and disposal. This manual is written in Chinese.
| Strengths | 100 mg/vial; 160 mg/vial |
|---|---|
| Active ingredient | Trastuzumab emtansine, a HER2-targeted antibody-drug conjugate (ADC) |
| Molecular weight | Approximately 148,781 Da |
| Excipients | Succinic acid, sodium hydroxide, polysorbate 20, sucrose |
| Dosage form | White to off-white sterile lyophilized powder for intravenous infusion |
| Recommended dose | 3.6 mg/kg by intravenous infusion once every 3 weeks (21-day cycle) |
| Reconstitution volume | 5 mL sterile water for injection for the 100 mg vial; 8 mL for the 160 mg vial |
The recommended dose is 3.6 mg/kg given by intravenous infusion once every 3 weeks, with a 21-day cycle.
The product is supplied in 100 mg/vial and 160 mg/vial strengths.
No. It must be given as an intravenous infusion and must not be given as an intravenous push or rapid intravenous injection.
The starting dose is given as a 90-minute intravenous infusion, with observation during the infusion and for at least 90 minutes afterwards.